| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.30400 |
| P698 | PubMed publication ID | 27906458 |
| P50 | author | Didier Blaise | Q88013295 |
| Tomasz Czerw | Q88230103 | ||
| Myriam Labopin | Q89534568 | ||
| P2093 | author name string | Mohamad Mohty | |
| Depei Wu | |||
| Arnon Nagler | |||
| William Arcese | |||
| Ellen Meijer | |||
| Tsila Zuckerman | |||
| Thomas Pabst | |||
| Anne Huynh | |||
| Emmanuelle Polge | |||
| Jan Cornelissen | |||
| Damir Nemet | |||
| Seckin Cagirgan | |||
| Norbert-Claude Gorin | |||
| Pierre-Yves Dumas | |||
| Mohamed Houhou | |||
| Silvia Maria Trisolini | |||
| P2860 | cites work | Autologous peripheral blood stem cell transplantation for acute myeloid leukemia | Q84997846 |
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission | Q28290182 | ||
| Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
| Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. | Q33628596 | ||
| Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. | Q33978951 | ||
| Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. | Q34255145 | ||
| Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study | Q34369800 | ||
| High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study | Q34996058 | ||
| Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis | Q35622255 | ||
| Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia | Q36925156 | ||
| Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma | Q38102892 | ||
| Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects | Q38568355 | ||
| Hematopoietic stem cell transplantation for patients with AML in first complete remission | Q38667488 | ||
| CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma | Q39098372 | ||
| Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood an | Q40831363 | ||
| Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia? | Q42183914 | ||
| BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. | Q43267402 | ||
| Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. | Q45178979 | ||
| Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. | Q53001093 | ||
| Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. | Q53147155 | ||
| Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. | Q53346464 | ||
| A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B | Q71127546 | ||
| Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests | Q77977077 | ||
| Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience | Q79354265 | ||
| P433 | issue | 5 | |
| P921 | main subject | acute leukemia | Q976388 |
| P304 | page(s) | 824-831 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) | |
| P478 | volume | 123 |
| Q58716610 | Autologous Transplantation for Older Adults with AML |
| Q92934940 | Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia |
| Q92259323 | Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia? |
| Q36121885 | Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT |
Search more.